知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

783 条记录 (耗时 0.055 秒)

    Synthetic Herpes Simplex Viruses Type-1 for Treatment of Cancers
    44.
    发明申请
    Synthetic Herpes Simplex Viruses Type-1 for Treatment of Cancers 有权
    合成单纯疱疹病毒1型治疗癌症

    公开(公告)号：US20100297085A1

    公开(公告)日：2010-11-25

    申请号：US12598937

    申请日：2008-05-09

    申请人： Konstantin G. Kousoulas

    发明人： Konstantin G. Kousoulas

    IPC分类号： A61K35/76 ,  C12N7/00 ,  C12N15/63 ,  A61P35/00

    CPC分类号： C07K14/005 ,  A61K35/763 ,  C12N7/00 ,  C12N2710/16622 ,  C12N2710/16632 ,  C12N2710/16662

    摘要： A recombinant herpes simplex virus type-1 (HSV-1) has been constructed that carries a deletion of one of the two viral γ1 34.5 genes and other immediate early genes, which render the virus able to selectively replicate in cancer cells but not efficiently replicate in normal cells, and in which specific mutations have been introduced to enable the virus to spread among cancer cells by virus-induced fusion. Specifically, syncytial mutations have been introduced in the genes coding for glycoprotein B and glycoprotein K of the virus, enabling high replication and spread of the virus in cancer cells in the presence of substantially lower amounts of γ1 34.5 protein, which is required for optimum infectious virus produced and virus-induced cell fusion. Other known syncytial mutations could also be introduced that would render the virus able to cause extensive virus-induced cell fusion. In addition, other known mutations can be introduced to limit the spread of the virus to the nervous system. These altered viruses or the isolated bacterial chromosomes could be used to treat various cancers including breast, liver, colon, and other tissues.

    摘要翻译： 已经构建了重组的单纯疱疹病毒1型（HSV-1），其携带两种病毒γ134.5基因和其他立即早期基因之一的缺失，这使得该病毒能够在癌细胞中选择性复制但不能有效复制 在正常细胞中，并且其中引入了特异性突变以使病毒能够通过病毒诱导的融合在癌细胞中扩散。 具体来说，在编码病毒的糖蛋白B和糖蛋白K的基因中引入了合胞体突变，使得在存在显着更低量的γ134.5蛋白质的情况下能够在癌细胞中高度复制和扩散，这是最佳感染性 病毒产生和病毒诱导的细胞融合。 还可以引入其他已知的合胞体突变，这将使病毒能够引起广泛的病毒诱导的细胞融合。 此外，可以引入其他已知的突变以限制病毒传播到神经系统。 这些改变的病毒或分离的细菌染色体可用于治疗各种癌症，包括乳腺癌，肝癌，结肠癌和其他组织。

    Immunological herpes simplex virus antigens and methods for use thereof
    47.
    发明授权
    Immunological herpes simplex virus antigens and methods for use thereof 有权
    免疫性单纯疱疹病毒抗原及其使用方法

    公开(公告)号：US07744903B2

    公开(公告)日：2010-06-29

    申请号：US11055477

    申请日：2005-02-10

    申请人： David M. Koelle ,  Lawrence Corey

    发明人： David M. Koelle ,  Lawrence Corey

    IPC分类号： A61K39/245

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K2039/55572 ,  A61K2039/57 ,  C07K2319/00 ,  C12N2710/16622 ,  C12N2710/16634

    摘要： The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

    摘要翻译： 本发明提供可用于预防和治疗HSV感染的HSV抗原。 本文公开了抗原和/或其组成表位，其被证实被来自疱疹病变或子宫颈的T细胞识别。 对本发明的抗原具有特异性的T细胞已经证明了对负载有病毒编码的肽表位的细胞的细胞毒性活性，并且在许多情况下，针对感染HSV的细胞。 鉴定负责T细胞特异性的免疫原性抗原提供了改进的抗病毒治疗和预防策略。 含有编码本发明抗原的抗原或多核苷酸的组合物提供有效靶向的疫苗，用于预防和治疗HSV感染。